Phase I trials typically involve a small group of participants, generally between 20 to 80 people. The process begins with a low dose of the treatment, which is gradually increased. Patients are closely monitored for side effects and adverse reactions. The goal is to identify the safe dosage range and understand the treatment's pharmacokinetics and pharmacodynamics.
